ASENAPINE |
SYCREST |
Drug Class | antipsychotic agents |
Year of Approval | 2009 |
FDA Approval | approved |
Drug Class | Small molecule |
Drug Indications | antipsychotic agent |
Drug Categories | acid reducers |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents that produce hypertension |
Drug Categories | antidepressive agents |
Drug Categories | cytochrome p-450 cyp2d6 inhibitors (weak) |
Drug Categories | cytochrome p-450 cyp2d6 substrates |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine antagonists |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | histamine antagonists |
Drug Categories | histamine h1 antagonists |
Drug Categories | histamine h2 antagonists |
Drug Categories | neurotoxic agents |
Drug Categories | qtc prolonging agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin agents |
Drug Categories | serotonin receptor agonists |
Drug Categories | ugt1a4 substrates |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
agonist (activating) |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Full agonist |
Trial Name | Asenapine |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
Direct Interaction? | True |
agonist (activating) |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
Endogenous Drug? | False |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Trial Name | Asenapine |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
antagonist (inhibitory) |
Trial Name | Asenapine |
Novel drug target | Established target |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
65576-45-6 | CAS Number |
Saphris | Drug Brand |
Secuado | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | acid reducers |
Drug Indications | antipsychotic agent |
Drug Class | Small molecule |
FDA Approval | approved |
Year of Approval | 2009 |
Drug Class | antipsychotic agents |
D00JRA | TTD Drug ID |